Lilly Deutschland GmbH., Sanofi-Aventis Deutschland GmbH secures contract for Pharmaceutical products - conclusion of a non-exclusive discount agreement in accordance with Section 130a paragraph 8 SGB V for the active ingredient insulin lispro, ATC A10AB04, A10AD04 f d time 010124 - 311224 (plus extension option 1x12 months)

Germany, Jan. 13 -- Germany based Lilly Deutschland GmbH., Sanofi-Aventis Deutschland GmbH has secured contract from DAK-Gesundheit for Pharmaceutical products - conclusion of a non-exclusive discount agreement in accordance with Section 130a paragraph 8 SGB V for the active ingredient insulin lispro, ATC A10AB04, A10AD04 f d time 010124 - 311224 (plus extension option 1x12 months). The value of the contract is not disclosed.

Published by HT Digital Content Services with permission from Pivotal Sources....